Elevation of IGFBP6 also promoted the immune process, especially Type-II-IFN response, and responses to immunotherapy, suggesting that IGFBP6 might be a candidate immunotherapeutic target for BC. The gene discussed is IGFBP6; the disease is breast cancer.